These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17627561)

  • 1. Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
    Ashton JC; Smith PF
    Curr Vasc Pharmacol; 2007 Jul; 5(3):175-85. PubMed ID: 17627561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
    [No Abstract]   [Full Text] [Related]  

  • 3. End of the line for cannabinoid receptor 1 as an anti-obesity target?
    Jones D
    Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.
    Mukhopadhyay P; Bátkai S; Rajesh M; Czifra N; Harvey-White J; Haskó G; Zsengeller Z; Gerard NP; Liaudet L; Kunos G; Pacher P
    J Am Coll Cardiol; 2007 Aug; 50(6):528-36. PubMed ID: 17678736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
    Mach F; Montecucco F; Steffens S
    Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 11. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
    Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 13. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 antagonists for obesity--what lessons have we learned from rimonabant?
    Di Marzo V; Després JP
    Nat Rev Endocrinol; 2009 Nov; 5(11):633-8. PubMed ID: 19844251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weeding out new drugs.
    Ewan S
    Drug Discov Today; 2005 Oct; 10(20):1336-7. PubMed ID: 16253865
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
    Andrikopoulos GK; Tzeis S
    Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.